Market Overview:
The global Lung Cancer Diagnostic and Screening Market is estimated to be valued at US$ 1,931.0 million in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period of 2023-2030, as highlighted in a new report published by Coherent Market Insights. The lung cancer diagnostic and screening market involves the testing and screening procedures for the detection and diagnosis of lung cancer. These procedures include diagnostic imaging tests, biomarker tests, genetic tests, endoscopy, and biopsy among others. The market offers various advantages such as early detection of lung cancer, which helps in timely treatment and increased survival rates. It also supports effective monitoring and surveillance of patients, allowing healthcare professionals to tailor individualized treatment plans. Market Key Trends: The key trend in the lung cancer diagnostic and screening market is the emergence of liquid biopsy as a non-invasive diagnostic tool. Liquid biopsy allows the detection of tumor-related genetic mutations and biomarkers through the analysis of blood samples. This technique eliminates the need for invasive procedures like surgery or biopsy, making it more convenient and patient-friendly. Liquid biopsy also enables real-time monitoring of the disease progression and treatment response, facilitating personalized treatment approaches for lung cancer patients. The adoption of liquid biopsy is driven by the increasing demand for minimally invasive diagnostic techniques and the growing awareness about the benefits of early cancer detection. Moreover, advancements in molecular diagnostics and genetic testing technologies have further enhanced the accuracy and reliability of liquid biopsy in the diagnosis and monitoring of lung cancer. Overall, the global lung cancer diagnostic and screening market is poised for significant growth, fueled by technological advancements and the increasing prevalence of lung cancer. The emergence of liquid biopsy as a key trend Segment Analysis: The lung cancer diagnostic and screening market can be segmented based on diagnostic method, end-user, and region. Based on diagnostic method, the market can be divided into imaging tests, biomarker tests, biopsy, and others. Among these, imaging tests dominate the market due to their wide availability and ease of use. Imaging tests, such as X-rays, CT scans, and PET scans, provide detailed images of the lungs, helping in the diagnosis and staging of lung cancer. These tests are widely preferred as they can detect abnormalities in the lungs even at early stages, increasing their adoption in lung cancer diagnostics. In terms of end-user, the market can be categorized into hospitals, diagnostic laboratories, and research institutes. Hospitals hold the largest share in the market as they are primary healthcare centers and have advanced infrastructure for lung cancer diagnosis and treatment. Moreover, hospitals have a higher patient footfall, leading to increased demand for lung cancer diagnostic tests. Key Takeaways: The Global Lung Cancer Diagnostic And Screening Market Size is expected to witness high growth, exhibiting a CAGR of 7.8% over the forecast period. The increasing prevalence of lung cancer, growing awareness about early detection and screening, and advancements in diagnostic technologies are driving market growth. In terms of regional analysis, North America is the fastest-growing and dominating region in the lung cancer diagnostic and screening market. The region has well-established healthcare infrastructure, high healthcare expenditure, and a large patient pool, leading to the adoption of advanced diagnostic techniques for lung cancer. The presence of key market players in the region further contributes to its dominance. Key players operating in the lung cancer diagnostic and screening market include Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc., F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc. These market players are focusing on launching innovative diagnostic tests, strategic collaborations, and mergers and acquisitions to strengthen their market position and enhance their product portfolio in the lung cancer diagnostic and screening market. Readmore:https://www.trendingwebwire.com/lung-cancer-diagnostic-and-screening-market-insights-trends/
0 Comments
|
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |